Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the very first-line remedy of CML-CP. Five hundred and nineteen individuals with newly diagnosed CML-CP were being randomly assigned to acquire dasatinib in a dose of one hundred mg after day-to-day (259 individuals) or https://travisuqmib.activoblog.com/29033792/t-1101-tosylate-things-to-know-before-you-buy